Notification

Pegloticase (Krystexxa®)


Notification Issue Date: 10/01/2018

This version of the policy will become effective 01/01/2019.

This policy was updated to communicate the Company's coverage position for pegloticase (Krystexxa®).



Medical Policy Bulletin


Title:Pegloticase (Krystexxa®)

Policy #:08.01.02d

This policy is applicable to the Company’s commercial products only. Policies that are applicable to the Company’s Medicare Advantage products are accessible via a separate Medicare Advantage policy database.


The Company makes decisions on coverage based on Policy Bulletins, benefit plan documents, and the member’s medical history and condition. Benefits may vary based on contract, and individual member benefits must be verified. The Company determines medical necessity only if the benefit exists and no contract exclusions are applicable.

When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition. This decision is based on the member’s current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.

This Medical Policy Bulletin document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy Bulletin will be reviewed regularly and be updated as scientific and medical literature becomes available. For more information on how Medical Policy Bulletins are developed, go to the About This Site section of this Medical Policy Web site.



Policy

Coverage is subject to the terms, conditions, and limitations of the member's contract.

MEDICALLY NECESSARY

Pegloticase (Krystexxa®) is considered medically necessary and, therefore, covered for the treatment of symptomatic chronic gout in adult individuals when both of the following criteria are met:
  • Failure to normalize uric acid levels to less than 6 mg/dL after at least three months of one xanthine oxidase inhibitor (e.g., allopurinol or febuxostat) at the maximum recommended dose, unless the individual is intolerant to, has had a toxic reaction to, or has a contraindication to taking xanthine oxidase inhibitors.
  • Individual has at least one of the following:
    • at least three gout flares in the previous 18 months
    • at least one gout tophus
    • gouty arthritis

EXPERIMENTAL INVESTIGATIONAL

The use of pegloticase (Krystexxa®) for non-adults or for individuals with asymptomatic hyperuricemia, is considered experimental/investigational and, therefore, not covered because the safety and/or effectiveness of this use cannot be established by review of the available published peer-reviewed literature.

All other uses for pegloticase (Krystexxa®) are considered experimental/investigational and, therefore, not covered unless the indication is supported as an accepted off-label use, as defined in the Company medical policy on off-label coverage for prescription drugs and biologics.

REQUIRED DOCUMENTATION

The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the professional provider's office, hospital, nursing home, home health agencies, therapies, and test reports.

The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the drug.
Guidelines

Pegloticase (Krystexxa®) is administered by intravenous infusion; it should not be given as a push or bolus.

Pegloticase (Krystexxa®) is not recommended for the treatment of asymptomatic hyperuricemia.

BLACK BOX WARNINGS

Refer to the specific manufacturer's prescribing information for any applicable Black Box Warnings.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable benefit contract, pegloticase (Krystexxa®) is covered under the medical benefits of the Company’s products when the medical necessity criteria listed in this medical policy are met.

US FOOD AND DRUG ADMINISTRATION (FDA)

Pegloticase (Krystexxa®) was approved by the FDA on September 14, 2010, for treatment of individuals with chronic gout that is refractory to conventional therapy.

PEDIATRIC USE

The safety and effectiveness of pegloticase (Krystexxa®) in pediatric individuals have not been established.

Description

Pegloticase (Krystexxa®) is an intravenously administered uric acid--specific enzyme. It is a recombinant uricase (PEGylated) indicated for the treatment of symptomatic chronic gout in adults (18 years and older) who are refractory to the conventional therapy of xanthine oxidase inhibitors (e.g., allopurinol [Zyloprim] or febuxostat [Uloric™]) at the maximum recommended dose, unless intolerant, toxic, or contraindicated. Pegloticase (Krystexxa®) achieves its therapeutic effect by increasing the conversion of uric acid to allantoin, which lowers the serum uric acid level. The allantoin is then excreted by the kidneys.

BACKGROUND OF GOUT

Gout (monosodium urate crystal deposition disease) is a form of arthritis caused by a buildup of plasma uric acid (a by-product of protein metabolism). This uric acid buildup is known as hyperuricemia. There are two categories of hyperuricemia:
  • Primary hyperuricemia: lasts indefinitely and occurs in the absence of comorbidities or drugs that alter uric acid production or its excretion.
  • Secondary hyperuricemia: excessive urate production or decreased renal function resulting from disease, diet, drug, or toxin.

Individuals diagnosed with gout have usually had hyperuricemia for a considerable amount of time. Many individuals with hyperuricemia have no symptoms (asymptomatic hyperuricemia) for years. Gout manifests acutely with pain, inflammation, swelling, and, possibly, cellulitis. The knees and feet are usual sites of gout flares, but any joint is susceptible. Severe gout flares in the joints of the foot, especially the great toe, are referred to as podagra.

There are four stages of gout:
  • Asymptomatic phase: individual has no overt symptoms of gout but does have hyperuricemia and crystalline deposits into tissues.
  • Acute gouty arthritis: occurs after years of asymptomatic hyperuricemia.
  • Intercritical (interval) gout: there is a gap between flares, but individual is otherwise symptom free and has no joint problems.
  • Chronic recurrent and tophaceous (nodules composed of uric acid) gout: after many years of flares, this stage is disabling and involves permanent damage to joints and kidneys.

Gout may manifest as one or more of the following:
  • Recurrent acute inflammatory arthritis flares
  • Chronic arthropathy
  • Formation of tophaceous deposits (urate crystals)
  • Uric acid nephrolithiasis
  • Chronic nephropathy (due to comorbid states)

Acute gout flares may be treated with dietary changes (e.g., decreasing/abstinence from consumption of alcohol, fructose-sweetened drinks, meat, and seafood), non-steroidal anti-inflammatory drugs (NSAID), steroids and colchicine (Colcrys®). Chronic gout treatment usually includes antihyperuricemia medications.

PEER-REVIEWED LITERATURE

SUMMARY
The safety and effectiveness of pegloticase (Krystexxa®) was demonstrated in two replicate, multicenter, randomized, double-blind, placebo-controlled studies. The primary endpoint of both studies was the achievement of a plasma uric level of less than 6 mg/dL. Both studies reported a statistically significant lowering of the plasma uric levels (under 6 mg/dL) in those receiving pegloticase (Krystexxa®), compared to those receiving placebo.

OFF-LABEL INDICATIONS

There may be additional indications contained in the Policy section of this document due to evaluation of criteria highlighted in the Company’s off-label policy, and/or review of clinical guidelines issued by leading professional organizations and government entities.
References


American Hospital Formulary Service (AHFS). Pegloticase (Krystexxa®). Lexicomp Drug Information 2018. [Lexicomp Online Web site]. 12/2014. Available at:
http://online.lexi.com/lco/action/home [via subscription only]. Accessed August 23, 2018.

Becker MA. Asymptomatic hyperuricemia. 01/12/18. [UpToDate Web Site]. Available at: http://www.uptodate.com/contents/asymptomatic-hyperuricemia?source=search_result&search=Secondary+hyperuricemia&selectedTitle=1%7E150 . Accessed August 23, 2018.

Becker MA. Clinical manifestations and diagnosis of gout. 02/16/18. [UpToDate Web site]. Available at: http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-gout?source=machineLearning&search=Clinical+manifestations+and+diagnosis+of+gout&selectedTitle=1%7E150&sectionRank=1&anchor=H111564623#H111564623 [via subscription only]. Accessed August 23, 2018.

Centers for Disease Control and Prevention. Gout. [CDC Website]. Last reviewed 03/08/18. Available at: http://www.cdc.gov/arthritis/basics/gout.htm. Accessed August 23, 2018.

Elsevier’s Clinical Pharmacology Compendium. Pegloticase (Krystexxa®). 05/08/15. Available at: https://www.clinicalkey.com/pharmacology/ [via subscription only]. Accessed August 23, 2018.

Lexi-Drugs Compendium. Pegloticase (Krystexxa®). 08/17/18. [Lexicomp Online Web site]. Available at:
http://online.lexi.com/lco/action/home . [via subscription only]. Accessed August 23, 2018.

Pegloticase (Krystexxa®). [prescribing information] Lake Forest, WI: Horizon Pharma; 07/2018. Available at: http://www.krystexxa.com/ . Accessed August 23, 2018.

Sriranganathan MK, Vinik O, Bombardier C, Edwards CJ. Interventions for tophi in gout. Cochrane Database Syst Rev. 2014 Oct 20;10:CD010069. doi: 10.1002/14651858.CD010069.pub2.

Sundy J, Ganson N, Kelly S, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinent mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(4):1370.

Sundy J, Becker M, Baraf H, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-2891.

Truven Health Analytics Inc. Micromedex® Solutions. Pegloticase (Krystexxa®). [Micromedex® Web site]. 07/20/18. Available at: http://www.micromedexsolutions.com/micromedex2/librarian/ [via subscription only]. Accessed August 23, 2018.

US Food and Drug Administration (FDA). Center for Drug evaluation and Research. Drugs @FDA. Pegloticase (Krystexxa®) [FDA Website]. 07/2018. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed August 23, 2018.





Coding

Inclusion of a code in this table does not imply reimbursement. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

The codes listed below are updated on a regular basis, in accordance with nationally accepted coding guidelines. Therefore, this policy applies to any and all future applicable coding changes, revisions, or updates.

In order to ensure optimal reimbursement, all health care services, devices, and pharmaceuticals should be reported using the billing codes and modifiers that most accurately represent the services rendered, unless otherwise directed by the Company.

The Coding Table lists any CPT, ICD-9, ICD-10, and HCPCS billing codes related only to the specific policy in which they appear.

CPT Procedure Code Number(s)

N/A


Professional and outpatient claims with a date of service on or before September 30, 2015, must be billed using ICD-9 codes. Professional and outpatient claims with a date of service on or after October 1, 2015, must be billed using ICD-10 codes.

Facility/Institutional inpatient claims with a date of discharge on or before September 30, 2015, must be billed with ICD-9 codes. Facility/Institutional inpatient claims with a date of discharge on or after October 1, 2015, must be billed with ICD-10 codes.


ICD - 10 Procedure Code Number(s)

N/A


Professional and outpatient claims with a date of service on or before September 30, 2015, must be billed using ICD-9 codes. Professional and outpatient claims with a date of service on or after October 1, 2015, must be billed using ICD-10 codes.

Facility/Institutional inpatient claims with a date of discharge on or before September 30, 2015, must be billed with ICD-9 codes. Facility/Institutional inpatient claims with a date of discharge on or after October 1, 2015, must be billed with ICD-10 codes.


ICD -10 Diagnosis Code Number(s)

See Attachment A


HCPCS Level II Code Number(s)

J2507 Injection, pegloticase, 1 mg


Revenue Code Number(s)

N/A

Coding and Billing Requirements


Cross References

Attachment A: Pegloticase (Krystexxa®)
Description: ICD-10 Codes and Narratives




Policy History

08.01.02d
01/01/2019This policy was updated to communicate the Company's coverage position for pegloticase (Krystexxa®).


Effective 10/05/2017 this policy has been updated to the new policy template format.


Version Effective Date: 01/01/2019
Version Issued Date: 12/31/2018
Version Reissued Date: N/A

Connect with Us        


© 2017 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.